Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Opin Oncol. 2009 Jul;21(4):369-73. doi: 10.1097/CCO.0b013e32832c94bd.

Clinical implications of microsatellite instability in sporadic colon cancers.

Author information

  • 1Division of Oncology, Mayo Clinic, Rochester, Minnesota, USA. sinicrope.frank@mayo.edu

Abstract

PURPOSE OF REVIEW:

To review data demonstrating the prognostic and predictive impact of microsatellite instability (MSI) in human colon carcinomas.

RECENT FINDINGS:

MSI is a molecular marker of defective DNA mismatch repair that is detected in approximately 15% of sporadic colon cancers. Most, but not all retrospective studies, have shown that colon cancers with MSI have better stage-adjusted survival rates compared with non-MSI tumors. Furthermore, analyses of colon cancers from participants in randomized adjuvant therapy trials have suggested that MSI tumors do not benefit from treatment with 5-fluorouracil. Recent studies, including a pooled analysis, validate prior data demonstrating the prognostic and predictive impact of MSI status in colon cancer.

SUMMARY:

MSI is a molecular marker that can provide valuable prognostic and predictive information in colon cancer patients. In the appropriate clinical setting, MSI data can be used in clinical decision-making. Specifically, the favorable outcome of stage II colon cancers with MSI indicates that such patients should not receive adjuvant chemotherapy. Although data for stage III colon cancers with MSI suggest a lack of benefit from 5-fluorouracil alone, the benefit of the current standard treatment, 5-fluorouracil, leucovorin, and oxaliplatin, in this subgroup remains unknown and awaits further study.

PMID:
19444104
[PubMed - indexed for MEDLINE]
PMCID:
PMC3761884
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins Icon for PubMed Central
    Loading ...
    Write to the Help Desk